

	No.	1-year RS		5-year RS	
		%	(95% CI)	%	(95% CI)
<b>Acute myeloid leukemia (AML)<sup>†</sup></b>	13,230	43.0	(42.2–43.9)	25.4	(24.4–26.3)
<1 years	131	72.8	(64.2–79.7)	55.9	(44.9–65.5)
1–4 years	255	82.6	(77.3–86.8)	64.7	(57.7–70.9)
5–19 years	671	78.9	(75.6–81.8)	57.3	(52.9–61.4)
20–39 years	1,458	74.2	(71.8–76.3)	51.0	(48.1–53.9)
40–49 years	1,352	63.1	(60.5–65.7)	41.2	(38.2–44.2)
50–59 years	1,875	52.9	(50.6–55.1)	27.7	(25.3–30.2)
60–69 years	2,243	41.1	(39.0–43.1)	14.6	(12.9–16.5)
70–79 years	2,870	22.7	(21.2–24.3)	6.0	(4.9–7.3)
≥80 years	2,375	11.2	(9.9–12.6)	1.4	(0.7–2.4)
<b>Subtype and age</b>					
<b>Group 1</b>	10,890	39.6	(38.7–40.6)	21.1	(20.2–22.1)
AML, NOS; [M-9861]					
<1 years	41	80.8	(64.9–90.1)	56.4	(37.7–71.4)
1–4 years	85	81.1	(70.9–87.9)	64.6	(52.6–74.2)
5–19 years	190	72.9	(65.9–78.7)	47.2	(38.6–55.3)
20–39 years	463	71.2	(66.8–75.1)	43.4	(38.0–48.6)
40–59 years	1,220	52.5	(49.6–55.3)	26.3	(23.4–29.2)
≥60 years	3,758	21.3	(20.0–22.7)	6.0	(5.0–7.1)
AML with minimal differentiation; (FAB M0) [M-9872]					
<20 years	57	76.6	(63.0–85.7)	38.0	(22.7–53.2)
20–39 years	55	68.7	(54.5–79.3)	32.2	(19.2–46.0)
40–59 years	122	55.0	(45.7–63.4)	29.5	(21.2–38.3)
≥60 years	332	22.4	(18.0–27.2)	7.9	(4.6–12.3)
AML without maturation; (FAB M1) [M-9873]					
<20 years	46	73.9	(58.7–84.3)	56.1	(39.6–69.6)
20–39 years	107	75.6	(66.2–82.7)	49.2	(38.1–59.3)
40–59 years	229	59.2	(52.5–65.3)	32.6	(25.7–39.6)
≥60 years	397	28.3	(23.8–32.9)	5.6	(2.9–9.4)
AML with maturation; (FAB M2) [M-9874]					
<20 years	91	81.1	(71.4–87.8)	63.4	(51.9–72.8)
20–39 years	78	75.7	(64.6–83.8)	53.8	(41.1–64.8)
40–59 years	236	60.6	(54.0–66.6)	33.6	(27.0–40.4)
≥60 years	498	28.7	(24.6–32.9)	9.0	(5.9–12.8)
Acute myelomonocytic leukemia; (FAB M4) [M-9867]					
<20 years	107	74.8	(65.5–82.0)	50.1	(38.3–60.7)
20–39 years	144	75.5	(67.5–81.7)	44.1	(34.3–53.4)
40–59 years	339	54.9	(49.4–60.0)	31.2	(25.5–37.0)
≥60 years	690	24.9	(21.6–28.3)	5.5	(3.4–8.3)
Acute monoblastic and monocytic leukemia; (FAB M5) [M-9891]					
<20 years	123	74.1	(65.4–81.0)	57.8	(47.3–67.0)
20–39 years	118	63.6	(54.2–71.6)	36.6	(27.2–46.0)
40–59 years	280	52.3	(46.3–58.0)	30.2	(24.4–36.2)
≥60 years	481	21.3	(17.7–25.2)	7.8	(4.9–11.5)
Acute erythroid leukemia; (FAB M6) [M-9840]					
<20 years	11	~		~	
20–39 years	27	59.3	(38.7–75.1)	29.8	(13.1–48.7)
40–59 years	53	45.5	(31.8–58.3)	7.5	(0.9–24.1)
≥60 years	130	19.3	(12.9–26.8)	4.6	(1.3–11.4)
Acute megakaryoblastic leukemia; (FAB M7) [M-9910]					
<20 years	83	79.5	(69.0–86.8)	63.0	(50.4–73.2)
20–39 years	7	~		~	
40–59 years	23	~		~	
≥60 years	51	16.4	(7.6–28.0)	~	

	No.	1-year RS		5-year RS	
		%	(95% CI)	%	(95% CI)
Acute basophilic leukemia; [M-9870]					
<20 years	0	~		~	
20–39 years	0	~		~	
40–59 years	2	~		~	
≥60 years	2	~		~	
Acute panmyelosis; [M-9931]					
<20 years	2	~		~	
20–39 years	6	~		~	
40–59 years	24	~		~	
≥60 years	66	64.5	(51.0–75.1)	26.9	(14.7–40.6)
Myeloid sarcoma; [M-9930]					
<20 years	11	~		~	
20–39 years	15	~		~	
40–59 years	37	65.1	(47.5–78.1)	51.9	(33.1–67.8)
≥60 years	53	25.5	(14.5–38.1)	13.3	(5.3–25.1)
<b>Group 2</b>	<b>1,478</b>	<b>69.5</b>	<b>(67.0–71.8)</b>	<b>60.8</b>	<b>(57.9–63.6)</b>
AML with t(8;21); (FAB M2, t(8;21)) [M-9896]					
<20 years	31	93.5	(76.4–98.4)	79.2	(59.3–90.1)
20–39 years	45	73.4	(57.9–84.0)	49.4	(32.9–63.9)
40–59 years	65	68.0	(55.1–77.9)	41.4	(28.4–54.0)
≥60 years	79	38.2	(27.2–49.0)	18.5	(9.2–30.3)
AML with abnormal marrow eosinophils; inv(16) or t(16;16); (FAB M4Eo) [M-9871]					
<20 years	17	~		~	
20–39 years	39	79.3	(62.8–89.1)	74.1	(57.1–85.2)
40–59 years	48	83.6	(69.5–91.6)	58.1	(39.4–72.9)
≥60 years	34	41.6	(24.6–57.8)	32.4	(15.3–50.8)
APL with t(15;17); (FAB M3) [M-9866]					
<20 years	133	85.7	(78.5–90.7)	76.0	(66.5–83.2)
20–39 years	303	83.2	(78.5–87.0)	77.2	(71.5–81.9)
40–59 years	364	73.1	(68.2–77.4)	67.9	(62.3–72.8)
≥60 years	248	45.8	(39.3–52.1)	42.5	(35.5–49.3)
AML, 11q23 abnormalities; [M-9897]					
<20 years	11	~		~	
20–39 years	11	~		~	
40–59 years	12	~		~	
≥60 years	38	44.0	(27.5–59.4)	~	
<b>Group 3</b>	<b>862</b>	<b>39.7</b>	<b>(36.4–43.1)</b>	<b>13.3</b>	<b>(10.5–16.5)</b>
AML with myelodysplasia-related changes; [M-9895]					
<20 years	15	~		~	
20–39 years	33	84.9	(67.4–93.5)	47.6	(28.8–64.1)
40–59 years	161	53.4	(45.4–60.8)	23.2	(16.3–30.8)
≥60 years	573	27.8	(24.1–31.7)	5.2	(3.2–7.9)
Therapy-related myeloid neoplasms; [M-9920, 9987]					
<20 years	3	~		~	
20–39 years	7	~		~	
40–59 years	12	~		~	
≥60 years	58	67.1	(52.2–78.3)	12.6	(2.5–31.4)

	No.	1-year RS		5-year RS	
		%	(95% CI)	%	(95% CI)
<b>Precursor lymphoblastic leukemia/lymphoma (ALL/L)<sup>††</sup></b>	7,395	83.3	(82.5–84.2)	64.9	(63.6–66.2)
<1 years	132	80.1	(72.0–86.0)	58.2	(48.1–67.0)
1–4 years	1,984	98.3	(97.6–98.7)	91.2	(89.5–92.7)
5–19 years	2,528	93.8	(92.7–94.6)	80.5	(78.6–82.2)
20–39 years	1,090	77.8	(75.2–80.2)	41.7	(38.0–45.2)
40–49 years	474	67.5	(63.0–71.5)	29.3	(24.3–34.5)
50–59 years	447	59.8	(55.0–64.2)	22.5	(18.0–27.3)
60–69 years	330	50.1	(44.5–55.5)	17.0	(12.1–22.6)
70–79 years	262	34.8	(28.9–40.7)	10.2	(6.2–15.4)
≥80 years	148	20.1	(13.7–27.3)	3.6	(0.8–10.1)
<b>Subtype and age</b>					
B-cell lymphoblastic leukemia/lymphoma; [M-9727(B), 9728, 9835(B), 9836]					
<1 years	94	81.4	(71.7–88.0)	54.3	(41.6–65.4)
1–4 years	1,504	98.7	(98.0–99.2)	91.8	(89.7–93.5)
5–19 years	1,569	95.3	(94.2–96.3)	82.7	(80.4–84.9)
20–39 years	674	78.5	(75.2–81.5)	38.2	(33.5–42.9)
40–59 years	638	64.9	(61.0–68.4)	23.7	(19.7–28.0)
≥60 years	452	40.4	(35.7–45.0)	11.4	(7.9–15.7)
T-cell lymphoblastic leukemia/lymphoma; [M-9727(T), 9729, 9835(T), 9837]					
<1 years	4	~		~	
1–4 years	99	93.9	(87.0–97.2)	77.6	(66.6–85.4)
5–19 years	520	89.2	(86.2–91.6)	72.8	(68.2–76.8)
20–39 years	286	80.1	(74.9–84.3)	49.0	(41.7–55.8)
40–59 years	159	67.0	(59.0–73.7)	38.7	(30.5–46.8)
≥60 years	78	46.8	(34.9–57.8)	20.2	(10.1–32.8)
Lymphoblastic leukemia/lymphoma, unknown lineage; [M-9727(U), 9835(U)]					
<1 years	34	76.9	(58.6–87.9)	63.8	(44.7–77.9)
1–4 years	381	97.7	(95.5–98.8)	92.4	(88.6–95.0)
5–19 years	439	93.4	(90.6–95.4)	81.4	(76.9–85.1)
20–39 years	130	69.1	(60.2–76.4)	40.0	(30.9–49.0)
40–59 years	124	54.0	(44.7–62.3)	20.7	(12.6–30.3)
≥60 years	210	33.3	(26.8–39.9)	12.5	(7.6–18.7)
<b>Acute leukemia of ambiguous lineage<sup>†</sup></b>	714	26.2	(22.9–29.6)	16.8	(13.3–20.5)
<b>Subtype and age</b>					
Acute undifferentiated leukemia; [M-9801]					
<20 years	48	76.8	(62.0–86.5)	60.4	(43.1–73.9)
20–39 years	45	55.0	(39.3–68.2)	33.7	(18.4–49.7)
40–59 years	65	29.4	(18.9–40.7)	15.9	(7.9–26.3)
≥60 years	425	10.9	(8.0–14.2)	3.0	(1.3–5.9)
Acute biphenotypic leukemia; [M-9805]					
<20 years	37	64.9	(47.3–77.9)	50.4	(31.9–66.3)
20–39 years	16	~		~	
40–59 years	36	50.2	(33.1–65.2)	27.2	(11.9–45.2)
≥60 years	42	7.5	(1.9–18.2)	0.0	

Abbreviations: SEER-17, 17 cancer registry areas of the Surveillance, Epidemiology and End Results Program; No., number; RS, relative survival; CI, confidence interval; ~ relative survival not calculated for <25 cases or for insufficient number of individuals available for follow-up; NOS, not otherwise specified; FAB, French-American-British classification; APL, acute promyelocytic leukemia; (B), B-cell immunophenotype; (T) cell immunophenotype; (U), immunophenotype not specified.

<sup>†</sup> Includes all International Classification of Diseases for Oncology, third edition (ICD-O-3) morphology codes specified within the respective subtype categories. ICD-0-3 codes are specified within brackets.

<sup>††</sup> Includes B-cell lymphoblastic leukemia (n=4,730; 5-year RS 66.0%, 95% CI (64.4%-67.7%)); B-cell lymphoblastic lymphoma (n=201; 5-year RS 58.8%, 95% CI (49.9%-66.6%)); T-cell lymphoblastic leukemia (n=677; 5-year RS 60.3%, 95% CI (56.0%-64.3%)); T-cell lymphoblastic lymphoma (n=469; 5-year RS 59.2%, 95% CI (53.8%-64.2%)); lymphoblastic leukemia, unknown lineage (n=1,280; 5-year RS 65.9%, 95% CI (62.8%-68.7%)); lymphoblastic lymphoma, unknown lineage (n=38; 5-year RS 58.2%, 95% CI (39.8%-72.7%)).